Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 5,227 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed Not applicable Interventional Results available

Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)

NCT01454947
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
Clinical Decision Support (CDS): Accountable Justifications, Audit and Feedback: Peer Comparison, CDS Order Sets: Suggested Alternatives
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Anaheim, California • Bell, California • Commerce, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

NCT00000826
View directory record Official record
Conditions
Bacterial Infections, Mycoses, HIV Infections
Interventions
Clarithromycin, Rifabutin, Sulfamethoxazole-Trimethoprim, Dapsone, Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 26, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor

NCT03423147
View directory record Official record
Conditions
Cesarean Section, Surgical Site Infection, Nosocomial Infection
Interventions
2% chlorhexidine gluconate cloth, 4% Chlorhexidine gluconate vaginal scrub
Drug
Lead sponsor
Angela Bianco
Other
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 26, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

NCT06605118
View directory record Official record
Conditions
Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

NCT00761462
View directory record Official record
Conditions
Infectious Diseases
Interventions
Ciprofloxacin, Non-quinolone antibiotic
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 16 Years
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
66
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 26, 2026, 10:14 PM EDT
Terminated Phase 3 Interventional Results available

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963
View directory record Official record
Conditions
Infection
Interventions
Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 26, 2026, 10:14 PM EDT
Completed No phase listed Observational

An Observational Study of Neurologic Function After COVID-19 Infection

NCT04564287
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 26, 2026, 10:14 PM EDT
Completed No phase listed Observational

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

NCT00000933
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 4 Interventional

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

NCT00002125
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Beverly Hills, California • Los Angeles, California • Redwood City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 10:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

NCT00822276
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 26, 2026, 10:14 PM EDT
Completed No phase listed Observational

Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures

NCT00475891
View directory record Official record
Conditions
Isolate, Linezolid
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318
View directory record Official record
Conditions
Healthy Participants
Interventions
REGN10933 + REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Day and older
Enrollment
3,303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
132
States / cities
Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 26, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

NCT00005920
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
L-743,872
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rahway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

NCT03385304
View directory record Official record
Conditions
Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture
Interventions
10% povidone-iodine (1% free iodine) in purified water, 4% chlorhexidine gluconate (CHG) in purified water
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1,638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 26, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

NCT05384249
View directory record Official record
Conditions
Uveitis
Interventions
Izokibep, Placebo
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 26, 2026, 10:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Transposable Elements in Septic Immune Aging

NCT06809868
View directory record Official record
Conditions
Sepsis, Sepsis and Septic Shock, Sepsis With Multiple Organ Dysfunction (MOD), Sepsis With Acute Organ Dysfunction, Sepsis, Severe, Sepsis at Intensive Care Unit, Sepsis, Severe Sepsis and Septic Shock, Sepsis, Septic Shock
Interventions
RNA and DNA Sequencing
Genetic
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 26, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis

NCT04103268
View directory record Official record
Conditions
Sepsis
Interventions
sepsis
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 17 Years
Enrollment
72 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

NCT00288418
View directory record Official record
Conditions
Bacterial Infections
Interventions
Central Venous Catheter
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery

NCT02836990
View directory record Official record
Conditions
Wound Infection
Interventions
Prevena Incision Management System, Dermabond
Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 26, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

NCT00708110
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Bakersfield, California • Long Beach, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 26, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT03922724
View directory record Official record
Conditions
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 10:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

NCT00571389
View directory record Official record
Conditions
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions
Not listed
Lead sponsor
BioCytics, Inc.
Industry
Eligibility
5 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2030
U.S. locations
1
States / cities
Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 26, 2026, 10:14 PM EDT